The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea
The formulation is backed by over 80 clinical trials and 200 scientific publications
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Subscribe To Our Newsletter & Stay Updated
